S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.95 (+1.83%)
AAPL   143.11 (+4.01%)
MSFT   260.86 (+3.29%)
FB   196.36 (+1.46%)
GOOGL   2,234.39 (+2.58%)
AMZN   2,152.65 (+0.04%)
TSLA   674.40 (+1.58%)
NVDA   169.59 (+1.59%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.00 (+1.60%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.62 (-3.41%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.95 (+1.83%)
AAPL   143.11 (+4.01%)
MSFT   260.86 (+3.29%)
FB   196.36 (+1.46%)
GOOGL   2,234.39 (+2.58%)
AMZN   2,152.65 (+0.04%)
TSLA   674.40 (+1.58%)
NVDA   169.59 (+1.59%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.00 (+1.60%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.62 (-3.41%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.95 (+1.83%)
AAPL   143.11 (+4.01%)
MSFT   260.86 (+3.29%)
FB   196.36 (+1.46%)
GOOGL   2,234.39 (+2.58%)
AMZN   2,152.65 (+0.04%)
TSLA   674.40 (+1.58%)
NVDA   169.59 (+1.59%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.00 (+1.60%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.62 (-3.41%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
S&P 500   3,973.75 (+1.86%)
DOW   31,880.24 (+1.98%)
QQQ   293.95 (+1.83%)
AAPL   143.11 (+4.01%)
MSFT   260.86 (+3.29%)
FB   196.36 (+1.46%)
GOOGL   2,234.39 (+2.58%)
AMZN   2,152.65 (+0.04%)
TSLA   674.40 (+1.58%)
NVDA   169.59 (+1.59%)
BABA   87.52 (+0.84%)
NIO   15.93 (-3.10%)
AMD   95.00 (+1.60%)
CGC   5.20 (-5.80%)
MU   69.59 (+1.00%)
T   20.75 (+1.72%)
GE   75.44 (+0.25%)
F   12.84 (+2.72%)
DIS   105.85 (+3.35%)
AMC   11.62 (-3.41%)
PFE   52.86 (+0.74%)
PYPL   81.19 (+0.81%)
NFLX   187.98 (+0.87%)
OTCMKTS:HKMPF

Hikma Pharmaceuticals (HKMPF) Stock Forecast, Price & News

$20.82
0.00 (0.00%)
(As of 05/20/2022 12:00 AM ET)
Add
Compare
Today's Range
$20.82
▼
$20.82
50-Day Range
$20.82
▼
$28.00
52-Week Range
$20.82
▼
$37.70
Volume
N/A
Average Volume
600 shs
Market Capitalization
$5.05 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.28
View Price History Chart DataSkip Price History Chart
30 days | 90 days | 365 days | Advanced Chart
Receive HKMPF News and Ratings via Email

Sign-up to receive the latest news and ratings for Hikma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Hikma Pharmaceuticals logo

About Hikma Pharmaceuticals

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Headlines

May 23, 2022 | americanbankingnews.com
Analysts Offer Predictions for Hikma Pharmaceuticals PLC's FY2026 Earnings (OTCMKTS:HKMPF)
May 8, 2022 | americanbankingnews.com
Morgan Stanley Lowers Hikma Pharmaceuticals (OTCMKTS:HKMPF) Price Target to GBX 2,100
May 5, 2022 | proactiveinvestors.com.au
FTSE 100 soars after Wall St 'relief rally' and ahead of Bank of England decision but Hikma drops
May 4, 2022 | americanbankingnews.com
Hikma Pharmaceuticals (OTCMKTS:HKMPF) Stock Rating Lowered by Zacks Investment Research
April 29, 2022 | finanznachrichten.de
Hikma Pharmaceuticals PLC: Hikma confirms that it has not signed a licensing agreement with Opiant Pharmaceuticals
April 29, 2022 | americanbankingnews.com
Hikma Pharmaceuticals (OTCMKTS:HKMPF) Rating Increased to Buy at Zacks Investment Research
April 25, 2022 | marketwatch.com
Hikma Pharmaceuticals Gets Low Support for Re-Election of Patrick Butler at AGM
April 20, 2022 | proactiveinvestors.com.au
FTSE 100 flat but Wall Street makes a positive start despite Netflix flop
April 13, 2022 | finance.yahoo.com
Cross River Announces Completion of Inaugural Drill Campaign at the McVicar Gold Project, NW Ontario
April 13, 2022 | finance.yahoo.com
Is Hikma Pharmaceuticals PLC's (LON:HIK) Stock's Recent Performance A Reflection Of Its Financial Health?
March 29, 2022 | finance.yahoo.com
Hikma Ventures invests in Tact.ai, an AI-powered customer engagement platform for life sciences companies
February 24, 2022 | marketwatch.com
Hikma Pharmaceutical FY EPS $1.807
February 24, 2022 | markets.businessinsider.com
Hikma Pharma FY21 Profit Down, Lifts Dividend; Stock Down
See More Headlines

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Private households
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:HKMPF
Previous Symbol
OTC:HKMPF
CUSIP
N/A
CIK
N/A
Web
www.hikma.com
Phone
442073992760
Fax
44-20-7399-2761
Employees
8,700
Year Founded
N/A

Sales & Book Value

Annual Sales
$2.55 billion
Price / Sales
1.98
Cash Flow
$2.41 per share
Price / Cash Flow
8.65
Book Value
$10.18 per share
Price / Book
2.05

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
0.29
Current Ratio
2.06
Quick Ratio
1.38

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
242,320,000
Free Float
N/A
Market Cap
$5.05 billion
Optionable
Not Optionable

Company Calendar

Today
5/23/2022
Fiscal Year End
12/31/2022

MarketRank™

Overall MarketRank™

1.17 out of 5 stars

Analyst Opinion: 0.0Community Rank: 4.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.9 5 -4 -3 -2 -1 -













Hikma Pharmaceuticals (OTCMKTS:HKMPF) Frequently Asked Questions

Is Hikma Pharmaceuticals a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hikma Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Hikma Pharmaceuticals stock.
View analyst ratings for Hikma Pharmaceuticals or view top-rated stocks.

How often does Hikma Pharmaceuticals pay dividends? What is the dividend yield for Hikma Pharmaceuticals?

Hikma Pharmaceuticals announced a Semi-Annual dividend on Friday, August 6th. Shareholders of record on Friday, August 20th will be paid a dividend of $0.18 per share on Monday, September 20th. The ex-dividend date is Thursday, August 19th.
View Hikma Pharmaceuticals' dividend history.

Who are Hikma Pharmaceuticals' key executives?
Hikma Pharmaceuticals' management team includes the following people:
  • Engineer Said Samih Taleb Darwazah, Exec. Chairman (Age 65, Pay $2.71M)
  • Mr. Sigurdur Oli Olafsson Ph.D., CEO & Exec. Director (Age 53, Pay $3.26M)
  • Mr. Mazen Samih Taleb Darwazah, Exec. Vice Chairman & Pres of MENA (Age 64, Pay $2.11M)
  • Mr. Khalid Waleed Hosny Al Nabilsi, Chief Financial Officer (Age 50)
  • Ms. Henriette Nielsen, Exec. VP of Bus. Operations
  • Dr. Shahin Fesharaki, Chief Scientific Officer
  • Mr. Hussein Arkhagha, Chief Counsel
  • Mr. Bassam Wael Rushdi Kanaan CFA, CPA, Exec. VP of Corp. Devel. and M&A (Age 57)
  • Ms. Susan Ringdal, Exec. VP of Strategic Planning & Global Affairs
  • Ms. Majda Labadi, Exec. VP of Organisational Devel.
What is Hikma Pharmaceuticals' stock symbol?

Hikma Pharmaceuticals trades on the OTCMKTS under the ticker symbol "HKMPF."

How do I buy shares of Hikma Pharmaceuticals?

Shares of HKMPF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Hikma Pharmaceuticals' stock price today?

One share of HKMPF stock can currently be purchased for approximately $20.82.

How much money does Hikma Pharmaceuticals make?

Hikma Pharmaceuticals has a market capitalization of $5.05 billion and generates $2.55 billion in revenue each year.

How many employees does Hikma Pharmaceuticals have?

Hikma Pharmaceuticals employs 8,700 workers across the globe.

What is Hikma Pharmaceuticals' official website?

The official website for Hikma Pharmaceuticals is www.hikma.com.

How can I contact Hikma Pharmaceuticals?

Hikma Pharmaceuticals' mailing address is 1 NEW BURLINGTON PLACE, LONDON X0, W1S 2HR. The company can be reached via phone at 442073992760, via email at [email protected], or via fax at 44-20-7399-2761.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits Financial Juice YouTube

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.